Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  Brainstorm Cell Therapeutics Inc    

BRAINSTORM CELL THERAPEUTICS INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Brainstorm Cell Therapeutics Inc : BrainStorm’s Clinical Trial is Fast-Tracked to Phase IIa, Representing a Major Milestone for the Company

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/07/2013 | 03:51pm CEST
January 7, 2013

BrainStorm's Clinical Trial is Fast-Tracked to Phase IIa,
Representing a Major Milestone for the Company

NEW YORK & PETACH TIKVAH, Israel-January 7, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Israeli Ministry of Health has fast-tracked its current Phase I/II ALS safety trial to a Phase IIa dose-escalating trial, significantly expediting the company's clinical development program and saving valuable time. The trial, which will evaluate the safety and preliminary efficacy of BrainStorm's NurOwn stem cell therapy candidate, will be launched immediately at the Hadassah Medical Center in Jerusalem.


The Ministry of Health approved acceleration to a Phase IIa trial based on evaluation of only 12 of the initial cohort of 24 patients in the company's Phase I/II trial at Hadassah. In the Phase IIa trial, the second group of 12 patients will receive combined intramuscular and intrathecal administration of NurOwn cells in three cohorts, with increasing doses. The study participants, who have already been recruited, will be followed for three to six months after transplantation.

"Acceleration to Phase IIa will save us critical time, enabling us to proceed much more quickly with achieving our goal of developing an effective treatment for ALS," commented Dr. Adrian Harel, BrainStorm's CEO.

Professor Dimitrios Karussis, Principal Investigator of BrainStorm's Phase I/II trial at Hadassah, commented: "Based on the positive results we have seen for the first 12 patients, we are eager to begin the next stage of clinical testing, and are delighted that the Ministry of Health has given us the green light to proceed to Phase IIa."

BrainStorm has been conducting a Phase I/II clinical trial in ALS patients at the Hadassah Medical Center in Jerusalem since June 2011, and plans to launch the Phase IIa study immediately. The company is also planning to expand its clinical development to the United States in 2013, pending FDA approval.  Towards that goal, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential",  and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.  The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRAINSTORM CELL THERAPEUTI
05/14BRAINSTORM CELL THERAPEUTICS : Announces First Quarter 2018 Financial Results an..
PU
05/14BRAINSTORM CELL THERAPEUTICS : Management's Discussion and Analysis of Financial..
AQ
05/14BRAINSTORM CELL THERAPEUTICS INC : Brainstorm Cell Therapeutics Inc. to Host Ear..
AC
04/11BRAINSTORM CELL THERAPEUTICS : to Present at ARM's 6th Annual Cell & Gene Therap..
PU
04/09BRAINSTORM CELL THERAPEUTICS : Letter To Shareholders
PU
03/29BRAINSTORM CELL THERAPEUTICS : Appoints Two Leading Thought Leaders in the Field..
AQ
03/20INSIDER TRADING ACTIVITY BRAINSTORM : BCLI) – COO Bought 5,000 shares of ..
AQ
03/20INSIDER TRADING ACTIVITY BRAINSTORM : BCLI) – Director Bought 5,700 share..
AQ
03/08BRAINSTORM CELL THERAPEUTICS INC : Brainstorm Cell Therapeutics Inc. to Host Ear..
AC
03/08BRAINSTORM CELL THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL..
AQ
More news
Financials ($)
Sales 2018 2,25 M
EBIT 2018 -21,2 M
Net income 2018 -19,1 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 39,2x
Capi. / Sales 2019 29,4x
Capitalization 88,1 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 10,0 $
Spread / Average Target 117%
EPS Revisions
Managers
NameTitle
Chaim Lebovits President & Chief Executive Officer
Jerold Chun Chairman
Ralph Z. Kern Chief Operating & Medical Officer
Eyal Rubin Chief Financial Officer & Treasurer
Yael Gothelf Vice President-Scientific & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BRAINSTORM CELL THERAPEUTICS INC88
CELLTRION, INC.--.--%32 036
IQVIA HOLDINGS INC4.64%20 818
LONZA GROUP1.63%20 226
INCYTE CORPORATION-29.71%14 505
NEKTAR THERAPEUTICS42.83%13 705